Journal of Clinical & Experimental Pharmacology

Abstract

Co-administration of glibenclamide and amlodipine induces resistance to hyperglycemic treatment in streptozotocin induced adapted/non adapted diabetic rats

Omonkhelin J Owolabi *,Eric K I Omogbai

It is a well known fact that diabetes co-exist with hypertension. In fact studies have shown that about 65 % of diabetics have hypertension. Amlodipine, a calcium channel blocker is a well known anti-hypertensive frequently prescribed, even in diabetes. Potassium adaptation combined with amlodipine has also been shown to reduce blood pressure. This research is geared towards assessing the effects of both amlodipine and potassium adaptation on diabetic rats treated with glibenclamide. Diabetes was induced using streptozotocin in rats both potassium adapted and non-adapted, thereafter glibenclamide (5 mg/kg) alone and a combination of glibenclamide (5 mg/kg) and amlodipine (5 mg/kg) were administered orally. The animals were separately kept in metabolic cages and their urine volume, levels of plasma glucose, plasma and urine creatinine/ creatinine clearance, the lipid profile, plasma and urine electrolytes/ urea were also determined 24 hours after drug administration. The blood glucose levels of the diabetic rats treated with only glibenclamide was significantly (p